{"id":"flovent-fluticasone-hfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1473","moleculeType":"Small molecule","molecularWeight":"500.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors in airway epithelial and immune cells, leading to suppression of pro-inflammatory cytokine and chemokine production. This reduces airway edema, mucus secretion, and recruitment of inflammatory cells, thereby improving airflow and reducing asthma symptoms. The HFA (hydrofluoroalkane) formulation delivers the drug directly to the lungs via metered-dose inhaler.","oneSentence":"Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:45.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT05363202","phase":"PHASE3","title":"To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma","status":"UNKNOWN","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2022-04-15","conditions":"Bronchial Asthma","enrollment":790},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT00071552","phase":"PHASE4","title":"Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01-31","conditions":"Asthma","enrollment":49},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02740543","phase":"PHASE2","title":"Biomarkers of Irritant-Induced and Allergic Asthma","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2013-12","conditions":"Asthma","enrollment":18},{"nctId":"NCT03879837","phase":"PHASE3","title":"Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-03-25","conditions":"Asthma","enrollment":1902},{"nctId":"NCT02024204","phase":"NA","title":"Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-04-09","conditions":"Lung Diseases, Medication Compliance","enrollment":60},{"nctId":"NCT02778867","phase":"PHASE2, PHASE3","title":"SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-05-20","conditions":"Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE)","enrollment":129},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT02610816","phase":"PHASE2, PHASE3","title":"Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-03-21","conditions":"Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs)","enrollment":67},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT00318708","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-06","conditions":"Asthma","enrollment":92},{"nctId":"NCT00370097","phase":"PHASE1","title":"FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-30","conditions":"Asthma","enrollment":16},{"nctId":"NCT02113436","phase":"PHASE4","title":"Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT01606306","phase":"PHASE3","title":"Individualized Therapy For Asthma in Toddlers","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-02","conditions":"Asthma, Wheezing","enrollment":300},{"nctId":"NCT00441441","phase":"PHASE3","title":"A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Asthma","enrollment":351},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT00400608","phase":"PHASE4","title":"A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Asthma","enrollment":28},{"nctId":"NCT01184118","phase":"NA","title":"DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-03","conditions":"Lung Disease","enrollment":36},{"nctId":"NCT01741285","phase":"PHASE4","title":"Effects of QVAR in Smokers With Asthma","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2013-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02266927","phase":"PHASE1","title":"A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2014-09","conditions":"Mild to Moderate Asthma","enrollment":28},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT00449046","phase":"PHASE3","title":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT01763463","phase":"","title":"WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01287351","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2004-01","conditions":"Asthma","enrollment":82903},{"nctId":"NCT01141439","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT01729351","phase":"","title":"Qvar Therapy in Smoking Asthmatics","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-11","conditions":"Asthma, Smoking","enrollment":7195},{"nctId":"NCT00404261","phase":"PHASE4","title":"Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":"Asthma","enrollment":132},{"nctId":"NCT00307970","phase":"PHASE4","title":"Impact of Anti-static Chamber/Mask","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-04","conditions":"Asthma","enrollment":12},{"nctId":"NCT00308932","phase":"PHASE4","title":"Effect of Age and Device on Delivery of Fluticasone","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-02","conditions":"Asthma","enrollment":60},{"nctId":"NCT00393991","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-07","conditions":"Asthma","enrollment":475},{"nctId":"NCT00394199","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":357},{"nctId":"NCT00747318","phase":"PHASE3","title":"A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Asthma","enrollment":280},{"nctId":"NCT00830102","phase":"PHASE2","title":"Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2004-10","conditions":"Asthma","enrollment":64},{"nctId":"NCT00393952","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":557},{"nctId":"NCT01141452","phase":"","title":"Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":815377},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT00394121","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-03","conditions":"Asthma","enrollment":400},{"nctId":"NCT00649025","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-03","conditions":"Asthma","enrollment":438},{"nctId":"NCT00734292","phase":"PHASE2","title":"Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Mild to Moderate Asthma","enrollment":39},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51},{"nctId":"NCT00646620","phase":"PHASE3","title":"Symbicort Onset of Action 1","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":48},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00657774","phase":"PHASE1","title":"A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-04","conditions":"Asthma","enrollment":160},{"nctId":"NCT00402207","phase":"NA","title":"The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2005-08","conditions":"Asthma","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":113,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flovent"],"phase":"phase_3","status":"active","brandName":"Flovent Fluticasone HFA","genericName":"Flovent Fluticasone HFA","companyName":"SkyePharma AG","companyId":"skyepharma-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}